We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
OMJJARA GlaxoSmithKline Australia Pty Ltd
Product name
OMJJARA
Accepted date
May-2024
Active ingredients
momelotinib dihydrochloride monohydrate
Proposed indication
For the treatment of disease-related splenomegaly.
Application type
A (new medicine)
Publication date
May-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.